2024
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes
Bender C, Wiedeman A, Hu A, Ylescupidez A, Sietsema W, Herold K, Griffin K, Gitelman S, Long S, Gottlieb P, Strock R, Chesshir L, Redondo M, Williams C, Clements M, Moore W, DiMeglio L, Legge M, Mullen M, Sanchez J, Spall M, Woerner S, Gaglia J, Resnick B, Bryant N, Krishfield S, Turley J, Koshy N, Mackey M, Guttmann-Bauman I, Fitch R, Bartholow L, Shelso J, Al Nofal A, Hanisch K, Casas L, Thurlow B, Gottschalk M, Hashiguchi M, Paglia L, Lam A, Sanda S, Torok C, Wesch R, Moore D, Russell W, Smith T, Brown A, Brendle F, Haller M, Cintron M, Baidal D, Matheson D, Blaschke C, Moran A, Pappensus E, Leschyshyn J, Street A. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Science Translational Medicine 2024, 16: eadn2404. PMID: 38718135, DOI: 10.1126/scitranslmed.adn2404.Peer-Reviewed Original ResearchConceptsRegulatory T cellsType 1 diabetesT cellsC-peptideFoxp3<sup>+</sup> regulatory T cellsNew-onset type 1 diabetesResidual B-cell functionPhase 1 clinical trialAutoimmune type 1 diabetesC-peptide preservationHigh-dose cohortPhase 2 randomized trialYears compared to placeboNew-onset T1DBaseline C-peptidePeripheral blood samplesSuppression in vitroDetected 1 weekMatching placeboAdoptive transferDouble-blindHigh-dosePrevent autoimmunityLow-doseFold expansion
2023
New‐onset type 1 diabetes in children and adolescents as postacute sequelae of SARS‐CoV‐2 infection: A systematic review and meta‐analysis of cohort studies
Rahmati M, Yon D, Lee S, Udeh R, McEVoy M, Kim M, Gyasi R, Oh H, Sánchez G, Jacob L, Li Y, Koyanagi A, Shin J, Smith L. New‐onset type 1 diabetes in children and adolescents as postacute sequelae of SARS‐CoV‐2 infection: A systematic review and meta‐analysis of cohort studies. Journal Of Medical Virology 2023, 95: e28833. PMID: 37264687, DOI: 10.1002/jmv.28833.Peer-Reviewed Original ResearchConceptsPooled effect sizeNew-onset T1DMSequelae of SARS-CoV-2 infectionNew-onset type 1 diabetesSARS-CoV-2 infectionMeta-analysis of cohort studiesSystematic reviewRisk ratioEffect sizeConfidence intervalsPublic health practitionersNational health registriesMeta-analysisType 1 diabetesDiabetic ketoacidosisPostacute sequelae of SARS-CoV-2 infectionPost-acute sequelae of SARS-CoV-2 infectionPost-acute sequelaeAssociated with higher riskHigh riskDerSimonian-Laird methodSARS-CoV-2Non-COVID-19Health registriesHealth practitioners
2022
The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis
Rahmati M, Keshvari M, Mirnasuri S, Yon D, Lee S, Shin J, Smith L. The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis. Journal Of Medical Virology 2022, 94: 5112-5127. PMID: 35831242, PMCID: PMC9350204, DOI: 10.1002/jmv.27996.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisNew-onset T1DDiagnosed T1D childrenDiabetic ketoacidosisType 1 diabetesHbA1c valuesT1D childrenMeta-analysisNew-onset type 1 diabetesPre-COVID-19 pandemic levelsRisk of T1DRandom-effects meta-analysisGlobal incidence rateMedian glucosePediatric patientsPhysician awarenessViral infectionRelative riskIncidence rateCoronavirus disease 2019Pre-COVID-19T1DHbA1cCOVID-19 pandemicPandemic levels
2021
Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis
Kravetz AM, Sanghavi P, Bhargava V, Shi RZ, Nally LM. Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis. AACE Clinical Case Reports 2021, 7: 315-319. PMID: 34522772, PMCID: PMC8426612, DOI: 10.1016/j.aace.2021.03.009.Peer-Reviewed Original ResearchDiabetic ketoacidosisType 1 diabetesAcute pancreatitisSevere hypertriglyceridemiaNew-onset type 1 diabetesZinc transporter 8 autoantibodiesGlutamic acid decarboxylase 65Islet cell antigen 512Hospital day 5Courses of plasmapheresisType 2 diabetesCourse of treatmentPancreatitis symptomsLifestyle modificationCutaneous xanthomasHospital admissionSerious complicationsClinical statusInsulin deficiencyIntravenous fluidsInsulin infusionLipemia retinalisEarly treatmentEarly initiationEffective treatment
2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityC-PeptideCD3 ComplexCD8-Positive T-LymphocytesChildCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2013
Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV. Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013, 36: 4030-4035. PMID: 24130350, PMCID: PMC3836135, DOI: 10.2337/dc13-1074.Peer-Reviewed Original ResearchConceptsUsual care groupC-peptide concentrationsType 1 diabetesΒ-cell functionHybrid closed-loop controlSAP therapyPump therapyContinuous glucose monitorNew-onset type 1 diabetesPeak C-peptide concentrationMixed-meal tolerance testSensor-Augmented Pump TherapyEarly intensive therapyΒ-cell preservationUsual care participantsDays of diagnosisC-peptide areaMultiple daily injectionsInsulin pump therapyDays/weekMean glucose concentrationMedian durationIntensive therapyPrimary outcomeDaily injections
2012
Year in Diabetes 2012: The Diabetes Tsunami
Sherwin R, Jastreboff AM. Year in Diabetes 2012: The Diabetes Tsunami. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4293-4301. PMID: 23185035, PMCID: PMC3513534, DOI: 10.1210/jc.2012-3487.BooksConceptsClinical trialsAmerican Diabetes Association/European AssociationNew-onset type 1 diabetesPrevalence of diabetesCurrent treatment optionsLarge clinical trialsRecent clinical trialsBenefits of exerciseDevelopment of obesityNormal glucose metabolismType 1 diabetesStudy of DiabetesΒ-cell functionNovel therapeutic targetCentral nervous systemObese childrenSignificant morbidityTreatment optionsEndocrine SocietyInpatient settingTreatment strategiesIndividualized careOptimal preventionGlucose metabolismOptimization of interventions
2002
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes
Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. Journal Of Clinical Investigation 2002, 109: 895-903. PMID: 11927616, PMCID: PMC150925, DOI: 10.1172/jci14114.Peer-Reviewed Original ResearchMeSH KeywordsAbataceptAdultAntigens, CDAntigens, DifferentiationAutoimmunityB7-1 AntigenB7-2 AntigenCD28 AntigensCell DivisionCTLA-4 AntigenDiabetes Mellitus, Type 1FemaleGlutamate DecarboxylaseHumansImmunoconjugatesInterferon-gammaInterleukin-13IsoenzymesMaleMembrane GlycoproteinsSignal TransductionT-LymphocytesConceptsGAD65-reactive T cellsType 1 diabetesAutoreactive T cellsT cellsB7-1New-onset type 1 diabetesPancreatic islet cell antigensInsulin-dependent type 1 diabetesGlutamic acid decarboxylase 65B7-2 engagementType 1A diabetesMemory T cellsStimulation ex vivoIslet cell antigensB7-2 moleculesT cell proliferationB7-1 costimulationAutoimmune diseasesCTLA-4Healthy controlsPathogenic roleSelective blockadeCytokine secretionHuman diabetesT lymphocytes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply